Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 18/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | BIRC3 | Q13489 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18839537 | 1.00 | MALT1 (0.39) | MALT1PLATHTR7TMEM97SIGMAR1 | |
| SCHEMBL18839535 | 1.00 | MALT1 (0.39) | MALT1PLATHTR7TMEM97SIGMAR1 | |
| SCHEMBL18839685 | 0.82 | MALT1 (0.40) | MALT1 | |
| SCHEMBL22408835 | 0.82 | MALT1 (0.40) | MALT1BIRC3 | |
| SCHEMBL18839669 | 0.82 | MALT1 (0.40) | MALT1BIRC3 | |
| SCHEMBL18839670 | 0.82 | MALT1 (0.40) | MALT1BIRC3 | |
| SCHEMBL22408834 | 0.82 | MALT1 (0.40) | MALT1 | |
| SCHEMBL18839687 | 0.82 | MALT1 (0.40) | MALT1 | |
| SCHEMBL18863083 | 0.81 | MALT1 (0.41) | MALT1HTR7TMEM97SIGMAR1FLT3 | |
| SCHEMBL17293034 | 0.81 | MALT1 (0.51) | MALT1HTR7TMEM97SIGMAR1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | MMEL1, PPME1, CTSC | MALT1 4/4885PLAT 2314/4885HTR7 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.